| 21.74 |  +0.11 / +0.51% |
Data as of 4:00pm ET | Day’s Change |
| 21.74 |  0.00 / 0.00% |
Volume: 2.3K |
| Three Therapeutic Approaches That Are Worthy of Your Due Diligence Jun 17 / MotleyFool.com | NewLink Genetics Corp Stock Sees Short Interest Expand By 16% Jun 13 / TheStreet.com |
| Previous close | 21.63 |
| Today’s open | 21.50 |
| Day’s range | 21.50 - 22.26 |
| Volume | 262,958 |
| Average volume (3 months) | 189,333 |
| Market cap | $553.8M |
| Dividend yield | -- |
| Earnings growth (last year) | +62.42% |
| Earnings growth (this year) | -22.14% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -9.88% |
| P/E ratio | NM |
| Price/Sales | 153.97 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| SGNTSagent Pharmaceutica... | -0.04 | -0.20% |
| ICPTIntercept Pharmaceut... | +5.40 | +16.36% |
| CMRXChimerix Inc | +1.52 | +7.12% |
| EBSEmergent BioSolution... | -0.52 | -3.47% |
| Next reporting date | August 13, 2013 |
| EPS forecast (this quarter) | -$0.32 |
| Annual revenue (last year) | $1.7M |
| Annual profit (last year) | -$23.3M |
| Net profit margin | -1,382.39% |
Sector Health Technology |
Industry Biotechnology |
Chairman, Chief Executive & Scientific Officer Charles J. Link, Jr., MD |
President, Chief Operating & Medical Officer Nicholas N. Vahanian, MD, MBA |
Corporate headquarters Ames, Iowa |
.
